Paterna, May 9, 2025 – CURAPATH, a global life sciences company specializing in the custom design, development, and manufacturing of advanced drug delivery systems, yesterday welcomed an institutional visit from Felipe Carrasco, Regional Secretary of Industry, Commerce, and Consumer Affairs, and Rafael Escamilla, Director of External Relations at IVACE, at its facilities in the Valencia Technology Park.
The visit allowed representatives of the Generalitat Valenciana to gain a closer understanding of the work CURAPATH performs as a CDMO (Contract Development and Manufacturing Organization), and its role as a pioneering pharmaceutical and biotech company in the Valencian Community, operating both nationally and internationally
During the visit, CURAPATH’s CEO Philippe Clavel, along with CTO Vicent Nebot and CFO Nicolas Serra, presented the company’s history, capabilities, and strategic projects, highlighting its key role in driving innovation and enhancing industrial and healthcare sovereignty in the region.
“CURAPATH was founded with the purpose of revolutionizing the pharmaceutical and biotech sectors through innovation, scientific excellence, and social commitment,” said Philippe Clavel. “We currently have a team of 100 highly qualified professionals and cutting-edge infrastructure in the Valencia Technology Park.” The company’s commitment to the pharmaceutical sector is reflected in one of its core values: safeguarding patient health and lives, patients who have already been treated with therapies produced by the company in clinical trials around the world.
With more than 10 years of experience, locations in Valencia and Boston (USA), and since April 2021 part of ARCLINE Investment Management, a U.S.-based private equity firm with over $8.9 billion in committed capital, CURAPATH has more than tripled its growth rate compared to the market. ARCLINE has made only three investments in Europe, one of them in Spain, reinforcing the company’s strategic value for the region.
The company operates in one of the most promising long-term fields: non-viral vector-based therapies, which are expected to grow between 20% and 25% annually over the next two decades. CURAPATH has also established itself as a leading employer in the region, with a strong commitment to attracting and developing talent. 100% of its staff benefit from individualized training and specialized development plans.
“CURAPATH acts as a driving force for sectoral growth, creating value chains that benefit both local suppliers and research centers and startups,” explained Vicent Nebot. “Our work strengthens the region’s industrial and healthcare sovereignty, generating highly qualified employment and attracting both talent and foreign investment.”
The company actively participates in the world’s leading industry events, such as BIO International Convention (Boston), INTERPHEX (New York), CPHI (Japan and Germany), TIDES (San Diego), and CRS (Philadelphia). It is also organizing the “International Congress on Pharmaceutical and Biotechnological Innovation – NANOTHERA Summit 2025”, to be held from September 8–10 at the City of Arts and Sciences in Valencia. “This event will bring together the leading global players in the sector and reinforce the Valencian Community’s positioning as a benchmark in biopharmaceutical innovation,” added Vicent Nebot.
Felipe Carrasco and Rafael Escamilla visited CURAPATH to learn more about the company’s activity and express their support for its strategic initiatives aimed at accelerating investments and positively boosting the region’s economic, social, and environmental impact.
The Regional Secretary showed particular interest in the company’s international activity and its main challenges in the coming years, in a forward-looking sector of strategic importance to the Valencian Community.
“At the Generalitat Valenciana, we strongly support initiatives like CURAPATH, a company that combines innovation, sustainable growth, and international projection. The pharmaceutical and biotech sectors are key to the future economic and industrial development of our region, and companies like CURAPATH serve as a model for their ability to generate qualified employment, attract investment, and position the Valencian Community as a strategic hub in Europe,” said Felipe Carrasco
The company, which is already generating a driving effect in the Valencian economy, has expressed its alignment with the objectives of the Valencian Territorial Strategy, focused on job creation, territorial development, and value generation. CURAPATH also emphasized the need for institutional support and joint efforts to develop internationally relevant innovative technologies that can attract and empower other economic players in the region.
“CURAPATH is a clear example of how public-private collaboration can accelerate the development of strategic technology sectors for the Valencian Community. Its commitment to innovation, connection with local talent, and positive impact on the regional business ecosystem make it a driving force company that deserves our full institutional support,” concluded Felipe Carrasco.
